About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD is traded on NASDQ Capital Markets.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.
InspireMD is traded on NASDQ Capital Markets.
Location: Israel, Tel Aviv District, Tel Aviv
Employees: 51-200
Total raised: $14.6M
Founded date: 2005
Investors 2
| Date | Name | Website |
| 06.11.2022 | Hercules C... | htgc.com |
| 30.08.2023 | OrbiMed | orbimed.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.07.2016 | - | $14.6M | - |
Mentions in press and media 16
| Date | Title | Description |
| 01.07.2024 | InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million | Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Sole... |
| 28.05.2024 | InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 | Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval (PMA) application to F... |
| 07.05.2024 | InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th | -Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment o... |
| 06.03.2024 | InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update | - |
| 15.05.2023 | InspireMD Announces Private Placement of Up to $113.6 Million | - |
| 15.05.2023 | InspireMD Announces Private Placement of Up to $113.6 Million | - |
| 12.05.2023 | InspireMD Announces May 16, 2023 as New Date for First Quarter 2023 Results Conference Call and Webcast | /EIN News/ -- - Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treat... |
| 25.10.2022 | InspireMD to Report Third Quarter 2022 Financial Results on November 8, 2022, and Provide Corporate Business Update | -Conference call and webcast to be held at 8:30 a.m. EDT- /EIN News/ -- TEL AVIV, Israel, Oct. 25, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatm... |
| 27.10.2021 | InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update -Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET- | InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update -Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET- Tel Aviv, Israel- October 26, 2021 - Inspire... |
| 26.10.2021 | InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update | TEL AVIV, Israel, Oct. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announc... |
Show more